[1] Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021 May 26.
[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615.
[3] Toscano, Cristiana (29 April 2021). "Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine" (PDF). WHO.
[4] Peshimam G, Farooq U (8 February 2021). "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. Islamabad. Retrieved 5 March 2021. its single-dose regimen and normal refrigerator storage requirement could make it a favourable option for many countries
[5] Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, Wu C, Zhong Z, Wang F, Duan X, Tian S, Wu L, Liu Y, Luo Y, Chen Z, Li F, Li J, Yu X, Ren H, Liu L, Meng S, Yan J, Hu Z, Gao L, Gao GF. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021 Mar 24:S1473-3099(21)00127-4.
[6] Genomic epidemiology of novel coronavirus - Global subsampling. https://nextstrain.org/ncov/global
[7] Naveca, F.G., Nascimento, V., de Souza, V.C. et al. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nat Med (2021).
[8] Wise J. Covid-19: The E484K mutation and the risks it poses. BMJ. 2021 Feb 5;372:n359.
[9] CDC. Weekly Updates by Select Demographic and Geographic Characteristics. Page last reviewed: May 26, 2021.
[10] Jerome I Tokars, Manish M Patel, Ivo M Foppa, Carrie Reed, Alicia M Fry, Jill M Ferdinands, Waning of Measured Influenza Vaccine Effectiveness Over Time: The Potential Contribution of Leaky Vaccine Effect, Clinical Infectious Diseases, Volume 71, Issue 10, 15 November 2020, Pages e633–e641.
[11] de Bruyn G. Cofactors that may influence vaccine responses. Curr Opin HIV AIDS. 2010;5(5):404-408.
[12] Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015;33(36):4422-4429.
[13] Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 May 17.
[14] 金鹏飞, 张力, 李靖欣,等. 科学理性解读COVID-19疫苗Ⅲ期临床保护效力数据.
[15] Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020 Sep 8;324(10):951-960.
[16] Psx A , Yz C , Yw A , et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial[J]. 2020.
[17] Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Jun;21(6):803-812.
[18] Riepler L , Rssler A , Falch A , et al. Comparison of Four SARS-CoV-2 Neutralization Assays[J]. Vaccines, 2020, 9(1):13.
[19] Mishra S K . Comparison of CPE NT and PRNT assays for estimating Neutralizing antibody titres against Japanese Encephalitis Virus. 2014.
[20] Hitchings MDT, et al. Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study. 2021. April 7th. https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1
[21] de Faria, et al. Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report. April 15th https://doi.org/10.1101/2021.04.12.21255308
[22] 新冠病毒疫苗接种技术指南(第一版)[J/OL]. 中国病毒病杂志:1-2[2021-05-31].https://doi.org/10.16505/j.2095-0136.2021.0018.